Let Activefol.io Invest in AMGN on Your Behalf.
- Active Investing
- Personalized Strategy
- Low Monthly Fees
Course of Action
Sentiment (10 days)
- Strong Buy
- Strong Sell
DAILY PRICE CHANGE VS SENTIMENT
Why Does Investing Using an Automated Portfolio Management Works?
Activefol.io is an advanced system designed to automate securities investing. It is designed to screens, monitors and auto-trades elite stocks like "AMGEN INC. (AMGN)" using its proprietary Artificial Intelligence. By using Activefol.io an investor augments its potential to accelerate his financial performance.
Converting your 401k to a Rollover IRA and systematically invest using ACTIVEFOL.IO from Stock Circles could be a great strategy to grow your retirement account while you still have a long horizon before retirement. Activefol.io proprietary portfolio manager invests in Large Cap US Stocks only to ensure that you are investing in highly liquid securities.
Based on historical performance, Activefol.io's model strategies historically outperformed the S&P since 2016. It holds the potential to grow retirement accounts quicker than passive investment vehicles using the same securities.Activefol.io provides systematic investment strategies that use price momentum to produce short-term trades to build wealth.
In the past 3 years, the system has outperformed the S&P. Activefol.io makes short-term trades. If these trades happen in a tax-deferred account, you do not get taxed until you start taking money out of the account. So if you start auto-trading today in your retirement account and invests for 10, 15, 20 years, imagine how much money a systematic strategy as the potential to create for you.
This investment system works great for tax-deferred accounts like Traditional and Roth IRAs. You can trade with a minimum of $25,000 in your account.
Activefol.io is very affordable. You will pay a low monthly management fee to use it. Using Activefol.io will usually pay for itself on the first successful trade of the month.
Systematic investing is powerful
Systematic investing with ACTIVEFOL.IO is easy. You do not need to know anything about stock investing. All you need to do is to set up your trading strategy and the automated portfolio manager will take care of the rest. Stock Circles offers a default strategy to help you get started. You can test the strategy in simulation mode free of charge today. Once comfortable with the outcome, suitable investors are ready to invest real money. You can then connect Activefol.io to your brokerage account and start to auto-trade.
Past performance does not guarantee future success. Activefol.io will do its best to take advantage of the market but if the market goes down for a long period of time then there is no money to be made and everyone holding these securities can be affected.
Activefol.io invests only elite stocks. By investing in the S&P 500®, Nasdaq 100™ and Dow 30™.
Activefol.io uses Artificial Intelligence concepts to screen, monitor and invest in securities. It monitors and invests on your behalf while you attend more important life events.
Take advantage of active investing strategies today by registering at stockcircles.com It's free to start in simulation mode.
There are clear benefits associated with Activefol.io to help you reach your financial goals. Activefol.io simplifies stock investing down to a few steps. It invests for you, using your personalized strategy, while you attend more important life events.
Using Activefol.io is like having a professional portfolio manager working for you to help you reach your financial goals.
Activefol.io actively trades which is different from passive investing. The platform is on the lookout working to maximize your potential every minute of every business day of the year. It trades on the news taking advantage of price changes and trends by listening into trader's communications and by validating this information with market data.
Activefol.io is one of the first automated portfolio managers to take advantage of Government grade listening technology that produces emotional and rational indicators.
Try Activefol.io today!
You can test your strategy in simulation mode, risk free, Stock Circles today.
Get started now - and see where active automated trading can take you.
Disclaimer: Past performance may not be indicative of future results. Activefol.io like other investment methods rely on favorable market conditions to provide positive outcomes.
AMGEN INC. (AMGN) News
Amgen Receives Positive CHMP Opinion To Add Overall Survival Results From The Phase 3 ASPIRE Study To KYPROLIS® (carfilzomib) Label
Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending a label variation for KYPROLIS® (carfilzomib) to include the final overall survival (OS) data from the Phase 3 ASPIRE trial. The ASPIRE trial demonstrated that the addition of KYPROLIS to lenalidomide and dexamethasone (KRd) reduced the risk of death by 21 percent versus lenalidomide and dexamethasone alone (Rd) and extended OS by 7.9 months in patients with relapsed or refractory multiple myeloma (median OS 48.3 months for KRd versus 40.4 months for Rd, HR = 0.79, 95 percent CI, 0.67 – 0.95; 1-sided p=0.0045).
"This latest positive CHMP opinion marks the second time Amgen will add overall survival data from a Phase 3 study to the label, further validating the fundamental role of KYPROLIS in treating patients with relapsed or refractory multiple myeloma," said David M. Reese, M.D., senior vice president of Translational Sciences and Oncology at Amgen. "This is a major step towards advancing KYPROLIS-based regimens as standard of care, and we look forward to the European Commission's decision later this year."
KYPROLIS is approved in the European Union (EU) for use in combination with lenalidomide and dexamethasone or with dexamethasone alone (Kd) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Kd regimen of twice-weekly KYPROLIS administered at 56 mg/m2 and the KRd regimen of twice-weekly KYPROLIS administered at 27 mg/m2 are the first and only therapeutic combinations to demonstrate consistently improved OS versus recent standards of care in two Phase 3 trials in relapsed or refractory multiple myeloma patients (Kd versus bortezomib and dexamethasone [Vd] and KRd versus Rd).
Since its approval in 2012, approximately 80,000 patients worldwide have received KYPROLIS. The KYPROLIS clinical program continues to focus on providing treatment options for physicians and patients for this frequently relapsing and difficult-to-treat cancer.Get Started today! - Risk Free